Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,227 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhanced Recovery After Spine Surgery

NCT02949518
View directory record Official record
Conditions
Enhanced Recovery After Surgery, Spine Surgery
Interventions
Enhanced Recovery Pathway (ERP) for Spine
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Performance of the Hedrocel(R) Cervical Fusion Device

NCT00758758
View directory record Official record
Conditions
Symptomatic Cervical Disc Disease
Interventions
Anterior Cervical Discectomy and Fusion
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Clearwater, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 20, 2026, 1:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Selpercatinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Stockton, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NCT05222165
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 20, 2026, 1:42 PM EDT
Active, not recruiting No phase listed Observational

MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

NCT05471128
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care Biopsy
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
29 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

NCT02269267
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
Imatinib (Stopping their TKI), Dasatinib (Stopping their TKI), Nilotinib (Stopping their TKI), Bosutinib (Stopping their TKI)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
16
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 1Phase 2 Interventional

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

NCT06661902
View directory record Official record
Conditions
Prostate Cancer
Interventions
Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

NCT07301268
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Astrocytoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

PROvenge Treatment and Early Cancer Treatment

NCT00779402
View directory record Official record
Conditions
Prostate Cancer
Interventions
Control, Sipuleucel-T
Other · Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
18
States / cities
Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 20, 2026, 1:42 PM EDT
Completed No phase listed Observational

CHARITE™ vs. ALIF 5-Year Follow-up

NCT00215332
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
CHARITE
Device
Lead sponsor
DePuy Spine
Industry
Eligibility
Not listed
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Golden, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 20, 2026, 1:42 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease

NCT03761563
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Fortilink IBF System with TETRAfuse Technology
Device
Lead sponsor
Xtant Medical
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Sherman Oaks, California • Lone Tree, Colorado • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 20, 2026, 1:42 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

NCT00135733
View directory record Official record
Conditions
Lichen Planus
Interventions
Amevive (Alefacept), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 20, 2026, 1:42 PM EDT
Recruiting No phase listed Observational

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

NCT05946278
View directory record Official record
Conditions
Age-Related Osteoporosis
Interventions
Sample collection for gene expression
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

TXA in Spinal Fusion

NCT04272606
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Tranexamic Acid, Saline Solution, Visual Acuity Exam, 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Drug · Diagnostic Test
Lead sponsor
Catherine R. Olinger
Other
Eligibility
18 Years to 90 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 20, 2026, 1:42 PM EDT
Completed No phase listed Observational

Fibergraft Interbody Fusion Retrospective

NCT03898232
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Degeneration, Spinal Stenosis
Interventions
Computed Tomography (CT) Scan of the Lumbar Spine
Radiation
Lead sponsor
Bone and Joint Clinic of Baton Rouge
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

NCT00000976
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Miami, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342
View directory record Official record
Conditions
Solid Tumor
Interventions
TL118 Capsule
Drug
Lead sponsor
Teligene US
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Glendale, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 1:42 PM EDT
Withdrawn Not applicable Interventional

Stand-Alone Cage Verus Anterior Plating for Anterior Cervical Discectomy and Fusion.

NCT03312192
View directory record Official record
Conditions
Degenerative Disc Disease, Cervical Spine Degeneration
Interventions
Interbody Cage, Interbody Cage and Anterior Plating
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 4 Interventional Results available

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

NCT00808665
View directory record Official record
Conditions
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions
Dexmedetomidine, 0.9% Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials

NCT03543878
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flicker
Device
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 20, 2026, 1:42 PM EDT